Kyrgyzstan vs Malawi: Death rate from cancer
Kyrgyzstan
64.71 deaths per 100,000 people
in 2021
Malawi
65.62 deaths per 100,000 people
in 2021
Kyrgyzstan rank
129th
Malawi rank
127th
Death rate from cancer over time
- Kyrgyzstan
- Malawi
How they compare
Malawi currently reports 65.62 deaths per 100,000 people against 64.71 deaths per 100,000 people in Kyrgyzstan, a difference of 0.91 deaths per 100,000 people.
Across all 22 years both countries report, Malawi has been ahead every year.
Kyrgyzstan ranks 129th and Malawi ranks 127th of 194 countries.
Malawi has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kyrgyzstan | Malawi | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 71 deaths per 100,000 people | 98.95 deaths per 100,000 people | 27.94 deaths per 100,000 people | Malawi |
| 2010s | 66.88 deaths per 100,000 people | 85.03 deaths per 100,000 people | 18.14 deaths per 100,000 people | Malawi |
| 2020s | 66.06 deaths per 100,000 people | 70.56 deaths per 100,000 people | 4.5 deaths per 100,000 people | Malawi |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Kyrgyzstan or Malawi?
- Malawi, at 65.62 deaths per 100,000 people against 64.71 deaths per 100,000 people in Kyrgyzstan as of 2021.
- What is the difference in death rate from cancer between Kyrgyzstan and Malawi?
- 0.91 deaths per 100,000 people, with Malawi ahead.
- How many years of comparable data are there for Kyrgyzstan and Malawi?
- 22 years are reported by both, from 2000 to 2021.
- How do Kyrgyzstan and Malawi rank globally for death rate from cancer?
- Kyrgyzstan ranks 129th and Malawi ranks 127th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.